Serzone-5HT2 will go off the market this month in Canada

November 2003

Serzone-5HT2 will go off the market this month in Canada.

Most, if not all, generic nefazodone products will follow.

So far, Health Canada hasn't mandated this. Nefazodone is associated with liver failure...liver transplants...even death.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

who should take ASA daily and how much they should take
Men's Health Cialis is now approved in Canada to treat erectile dysfunction
Cardiology new warnings about a potential interaction between cranberry juice and warfarin
Osteoporosis combo treatment for osteoporosis in postmenopausal women
Osteoporosis thiazide diuretics reduce the risk of fractures from osteoporosis
Periostat, a new low-dose doxycycline for periodontitis
Shingles Does the chickenpox vaccine (Varivax III, Varilrix) prevent shingles
Alzheimer's Disease Canadians are asking about memantine (Namenda) for Alzheimer's
severe acute respiratory syndrome (SARS) might make a comeback during flu season
link between atypical antipsychotics and diabetes
Serzone-5HT2 will go off the market this month in Canada
Hematology & Oncology Femara (letrozole) to prevent recurrent breast cancer
Infectious Diseases new injectable antibiotic called Invanz (IN-vance)
Infectious Diseases Which antibiotic suspensions really need to be kept refrigerated
Medication Errors Look- and sound-alike drug names are creating mistakes